DC Field | Value | Language |
---|---|---|
dc.contributor.author | W Y Song | - |
dc.contributor.author | Y S Song | - |
dc.contributor.author | Hyung Won Ryu | - |
dc.contributor.author | Sei-Ryang Oh | - |
dc.contributor.author | J T Hong | - |
dc.contributor.author | D Y Yoon | - |
dc.date.accessioned | 2017-08-29 | - |
dc.date.available | 2017-08-29 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1017-7825 | - |
dc.identifier.uri | 10.4014/jmb.1610.10012 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/17037 | - |
dc.description.abstract | In the human airway, mucus exists to protect the respiratory system as a primary barrier of the innate immune system. However, hyperexpressed mucus limits airflow, resulting in a decrease of lung function. Among more than 20 mucin family members, MUC5AC and MUC5B are major glycoproteins in human airway mucus. The epidermal growth factor receptor (EGFR) signaling pathway is one of the mechanisms of these mucins expression and specificity protein-1 (Sp1) transcription factor is the downstream signal of this pathway, playing pivotal roles in mucin expression. Even though there are some drugs for treating mucus hypersecretion, no drug has proven effects on humans. We found that the flavonoid tilianin regulated MUC5AC expression and also inhibited Sp1 phosphorylation. In this study, we investigated how tilianin would modulate EGFR signaling and regulate mucin production. In conclusion, tilianin inhibited MUC5AC expression mediated via modulating the EGFR-MEK-ERK-Sp1 signaling pathway in NCI-H292 human airway epithelial cells. This study may provide the basis for the novel treatment of mucus hypersecretion. | - |
dc.publisher | Korea Soc-Assoc-Inst | - |
dc.title | Tilianin inhibits MUC5AC expression mediated via down-regulation of EGFR-MEK-ERK-SP1 signaling pathway in NCI-H292 human airway cells | - |
dc.title.alternative | Tilianin inhibits MUC5AC expression mediated via down-regulation of EGFR-MEK-ERK-SP1 signaling pathway in NCI-H292 human airway cells | - |
dc.type | Article | - |
dc.citation.title | Journal of Microbiology and Biotechnology | - |
dc.citation.number | 1 | - |
dc.citation.endPage | 56 | - |
dc.citation.startPage | 49 | - |
dc.citation.volume | 27 | - |
dc.contributor.affiliatedAuthor | Hyung Won Ryu | - |
dc.contributor.affiliatedAuthor | Sei-Ryang Oh | - |
dc.contributor.alternativeName | 송원용 | - |
dc.contributor.alternativeName | 송용석 | - |
dc.contributor.alternativeName | 류형원 | - |
dc.contributor.alternativeName | 오세량 | - |
dc.contributor.alternativeName | 홍진태 | - |
dc.contributor.alternativeName | 윤도영 | - |
dc.identifier.bibliographicCitation | Journal of Microbiology and Biotechnology, vol. 27, no. 1, pp. 49-56 | - |
dc.identifier.doi | 10.4014/jmb.1610.10012 | - |
dc.subject.keyword | Chronic obstructive pulmonary disease | - |
dc.subject.keyword | Epidermal growth factor | - |
dc.subject.keyword | Mucin 5AC | - |
dc.subject.keyword | Specificity protein-1 | - |
dc.subject.keyword | Tilianin | - |
dc.subject.local | Chronic obstructive pulmonary disease | - |
dc.subject.local | Chronic obstructive pulmonary disease (COPD) | - |
dc.subject.local | chronic obstructive pulmonary disease | - |
dc.subject.local | Pulmonary disease, chronic obstructive | - |
dc.subject.local | Epidermal growth factor | - |
dc.subject.local | Epidermal growth factor (EGF) | - |
dc.subject.local | Mucin 5AC | - |
dc.subject.local | Specificity protein 1 | - |
dc.subject.local | Specificity protein-1 | - |
dc.subject.local | Tilianin | - |
dc.subject.local | tilianin | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.